Business
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Enrollment completed in both Phase 3 chronic spontaneous urticaria global registration studies (EMBARQ-CSU 1 and 2) six months ahead of guidance; Topline data expected in Q4 26; BLA submission planned for 2027Phase 3 cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) actively accruing Enrollment completed in Phase 2 prurigo nodularis and atopic dermatitis studies with topline data expected in 2026 Phase 1 CDX-622 Proof of Mechanism study in asthma initiatedCompany prepares
About this update from Celldex Therapeutics, Inc.
[{"type":"image","alt":"Celldex Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Celldex Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":124,"url":"https://media.zenfs.com/en/globenewswire.com/aef6fa6af72579028a194fa6d2556979"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TpOULqxD5vaZLQ0RK_Jt6A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/aef6fa6af72579028a194fa6d2556979","width":300,"height":124}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Enrollment completed in both Phase 3 chronic spontaneous urticaria global registration studies (EMBARQ-CSU 1 and 2) six months ahead of guidance; Topline data expected in Q4 26; BLA submission planned for 2027","length":209,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 3 cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) actively accruing ","length":99,"tagName":"p"}]},{"val":[{"type":"text","content":"Enrollment completed in Phase 2 prurigo nodularis and atopic dermatitis studies with topline data expected in 2026 ","length":114,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 1 CDX-622 Proof of Mechanism study in asthma initiated","length":60,"tagName":"p"}]},{"val":[{"type":"text","content":"Company prepares for landmark year of clinical readouts in 2026","length":63,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":545,"olType":false},{"type":"text","content":"HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2025 and provided a corporate update.","length":192,"tagName":"p"},{"type":"text","content":""The enthusiasm for barzolvolimab continues to build, driven by unparalleled efficacy data across multiple indications,” said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex. “This is underscored by the completion of enrollment in our Phase 3 CSU studies six months ahead of guidance and strong interest from clinical trial sites in our recently initiated Phase 3 study in cold urticaria and symptomatic dermographism.”","length":454,"tagName":"p"},{"type":"text","content":"“During 2026, we are excited for multiple important data readouts across our pipeline, including topline ...